Conference Coverage
ctDNA Monitoring of Patients With ER-Positive, HER2-Negative High Risk Breast Cancer During Adjuvant Endocrine Therapy
01/03/2024
Lajos Pusztai, MD, DPhil, Yale Cancer Center, New Haven, Connecticut,discussed results from the DARE study which analyzed the clinical utility of ctDNA monitoring during adjuvant endocrine therapy to detect molecular relapse before apparent recurrence.
These results were first reported at the 2023 San Antonio Breast Cancer Symposium.
Source:
Pusztai L, Kalashnikova E, Hobbs E, et al. Circulating tumor DNA (ctDNA) monitoring of estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) high risk breast cancer during adjuvant endocrine therapy. Presented at the 2023 San Antonio Breast Cancer Symposium; December 5-9; San Antonio, Texas. Abstract PS06-02
